Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: stockselect1 who wrote (1215)	1/22/2004 4:06:38 PM
From: Tomato	Read Replies (1) \| Respond to of 1833

biz.yahoo.com REALIZED GAIN ON MARKETABLE SECURITIES On August 30, 2002, the Company's equity interest in Axiom was converted into 441,446 shares of common stock of Sequenom pursuant to the merger of Axiom with a subsidiary of Sequenom. Upon the closing of the transaction, the Company recorded a realized gain of $823,189 with respect to the 338,761 shares of common stock of Sequenom received in the merger in the consolidated statement of operations for the year ended December 31, 2002. The value of the remaining 102,685 shares of common stock of Sequenom received in the merger and being held in escrow was recorded as a deferred gain on exchange of equity interest in the accompanying consolidated balance sheet. ******* After reading that, I'm still not sure how many shares KDUS has now. 441,446?